Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Crown

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Seminars in Oncology|August 1, 1993
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancerA D Seidman, L Norton, B S Reichman, et al.
Cancer|April 15, 1993
Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trialA Kritz, J P Crown, R J Motzer, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary reportA D Seidman, B S Reichman, J P Crown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline responseA D Seidman, B S Reichman, J P Crown, et al.
Oncology|October 1, 1994
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancerA D Seidman, L Norton, B S Reichman, et al.
Psychosomatic Medicine|November 1, 1992
An experimental analysis of classically conditioned nausea during cancer chemotherapyD H Bovbjerg, W H Redd, P B Jacobsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacyC Hudis, A Seidman, J Baselga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancerC A Hudis, A D Seidman, J P Crown, et al.
Oncogene|December 6, 2011
The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancerD J Brennan, D P O'Connor, H Laursen, et al.
Breast Cancer Research and Treatment|April 9, 2021
Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in IrelandL M McSorley, M Tharmabala, F Al Rahbi, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Seminars in Oncology|August 1, 1993
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancerA D Seidman, L Norton, B S Reichman, et al.
Cancer|April 15, 1993
Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trialA Kritz, J P Crown, R J Motzer, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary reportA D Seidman, B S Reichman, J P Crown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline responseA D Seidman, B S Reichman, J P Crown, et al.
Oncology|October 1, 1994
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancerA D Seidman, L Norton, B S Reichman, et al.
Psychosomatic Medicine|November 1, 1992
An experimental analysis of classically conditioned nausea during cancer chemotherapyD H Bovbjerg, W H Redd, P B Jacobsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacyC Hudis, A Seidman, J Baselga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancerC A Hudis, A D Seidman, J P Crown, et al.
Oncogene|December 6, 2011
The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancerD J Brennan, D P O'Connor, H Laursen, et al.
Breast Cancer Research and Treatment|April 9, 2021
Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in IrelandL M McSorley, M Tharmabala, F Al Rahbi, et al.
Pageof 4